Trial Profile

Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Gemcitabine (Primary) ; Zoledronic acid (Primary)
Indications Early breast cancer
Focus Therapeutic Use
Acronyms SUCCESS-A

Most Recent Events

05 Jun 2018 Results assessing the prognostic impact of circulating tumour cells to predict late recurrences during long-term follow-up (n=206) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2016 Results assessing circulating tumour cell counts (n=311) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
18 May 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com